IL189246A0 - Albumin fusion proteins - Google Patents
Albumin fusion proteinsInfo
- Publication number
- IL189246A0 IL189246A0 IL189246A IL18924608A IL189246A0 IL 189246 A0 IL189246 A0 IL 189246A0 IL 189246 A IL189246 A IL 189246A IL 18924608 A IL18924608 A IL 18924608A IL 189246 A0 IL189246 A0 IL 189246A0
- Authority
- IL
- Israel
- Prior art keywords
- fusion proteins
- albumin fusion
- albumin
- proteins
- fusion
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title 1
- 108010088751 Albumins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70752105P | 2005-08-12 | 2005-08-12 | |
| US71238605P | 2005-08-31 | 2005-08-31 | |
| US73272405P | 2005-11-03 | 2005-11-03 | |
| US77691406P | 2006-02-28 | 2006-02-28 | |
| US78136106P | 2006-03-13 | 2006-03-13 | |
| US81018206P | 2006-06-02 | 2006-06-02 | |
| US81368206P | 2006-06-15 | 2006-06-15 | |
| PCT/US2006/029391 WO2007021494A2 (fr) | 2005-08-12 | 2006-07-31 | Proteines de fusion avec l'albumine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL189246A0 true IL189246A0 (en) | 2008-08-07 |
Family
ID=37758042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL189246A IL189246A0 (en) | 2005-08-12 | 2008-02-04 | Albumin fusion proteins |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1924596A4 (fr) |
| JP (1) | JP2009504157A (fr) |
| KR (1) | KR20080071119A (fr) |
| AU (1) | AU2006280312A1 (fr) |
| BR (1) | BRPI0614761A2 (fr) |
| CA (1) | CA2618476A1 (fr) |
| EC (1) | ECSP088262A (fr) |
| IL (1) | IL189246A0 (fr) |
| MA (1) | MA29836B1 (fr) |
| MX (1) | MX2008001865A (fr) |
| NO (1) | NO20081233L (fr) |
| TN (1) | TNSN08064A1 (fr) |
| WO (1) | WO2007021494A2 (fr) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| US20040010134A1 (en) | 2000-04-12 | 2004-01-15 | Rosen Craig A. | Albumin fusion proteins |
| DK1463751T3 (da) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albuminfusionsproteiner. |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| EP1729795B1 (fr) | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| EP1816201A1 (fr) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée |
| CA2654055A1 (fr) | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Proteines de fusion d'albumine |
| US20100254944A1 (en) * | 2006-09-14 | 2010-10-07 | Mani Subramanian | Albumin Fusion Proteins |
| EP2423221B1 (fr) | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Épitopes de lymphocytes t régulateurs, compositions et utilisations de ceux-ci |
| RU2567667C2 (ru) | 2008-06-13 | 2015-11-10 | Проекто Де Биомедисина Сима, С.Л. | Конъюгаты для введения биологически активных соединений |
| EA023344B1 (ru) | 2009-01-16 | 2016-05-31 | Тева Фармасьютикал Индастриз Лтд. | Способ лечения или предотвращения нейтропении или лейкопении или снижения частоты возникновения инфекции, проявляющейся фебрильной нейтропенией |
| CN106986933A (zh) | 2009-02-11 | 2017-07-28 | 阿尔布梅迪克斯医疗公司 | 白蛋白变体和缀合物 |
| KR20100100254A (ko) * | 2009-03-05 | 2010-09-15 | (주)바이오큐어팜 | 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물 |
| BR112012004094A2 (pt) | 2009-08-24 | 2016-03-08 | Amunix Operating Inc | composições de fator vii de coagulação e métodos para fazer e usar as mesmas |
| RU2607374C2 (ru) * | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Варианты альбумина |
| KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| BR112012029611A2 (pt) | 2010-05-21 | 2017-07-25 | Merrimack Pharmaceuticals Inc | proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico |
| KR101969526B1 (ko) * | 2011-02-28 | 2019-04-17 | 고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터 | 악성 종양 전이 억제용 의약 |
| CN104011072B (zh) | 2011-05-05 | 2018-10-12 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2012170969A2 (fr) | 2011-06-10 | 2012-12-13 | Biogen Idec Ma Inc. | Composés pro-coagulants et leurs procédés d'utilisation |
| ES2527510T1 (es) | 2011-10-21 | 2015-01-26 | Abbvie Inc. | Métodos para el tratamiento del VHC que comprenden al menos dos agentes antivirales de acción directa, ribavirina pero no interferón |
| DE112012003457T5 (de) | 2011-10-21 | 2015-03-12 | Abbvie Inc. | Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV) |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
| MY201293A (en) | 2012-01-12 | 2024-02-15 | Bioverativ Therapeutics Inc | Chimeric factor viii polypeptides and uses thereof |
| RS63870B1 (sr) | 2012-02-15 | 2023-01-31 | Bioverativ Therapeutics Inc | Sastavi faktora viii i postupci za pravljenje i upotrebu istih |
| JP6383666B2 (ja) | 2012-02-15 | 2018-08-29 | バイオベラティブ セラピューティクス インコーポレイテッド | 組換え第ｖｉｉｉ因子タンパク質 |
| CA2861592A1 (fr) | 2012-03-16 | 2013-09-19 | Novozymes Biopharma Dk A/S | Variants d'albumine |
| EP2863940A4 (fr) | 2012-06-08 | 2016-08-10 | Biogen Ma Inc | Facteurs de coagulation chimériques |
| EP2858659B1 (fr) | 2012-06-08 | 2019-12-25 | Bioverativ Therapeutics Inc. | Composés pro-coagulants |
| CN103525695B (zh) * | 2012-07-04 | 2015-05-20 | 长沙中生众捷生物技术有限公司 | 便携式肾功能检测系统 |
| DK2882450T3 (da) | 2012-07-11 | 2020-02-24 | Bioverativ Therapeutics Inc | Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf |
| WO2014063108A1 (fr) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Procédés d'utilisation d'une dose fixe d'un facteur de coagulation |
| WO2014072481A1 (fr) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Variants d'albumine |
| HRP20231183T1 (hr) | 2013-02-15 | 2024-01-05 | Bioverativ Therapeutics Inc. | Optimizirani gen faktora viii |
| ES2648591T3 (es) | 2013-02-16 | 2018-01-04 | Albumedix A/S | Modelo animal farmacocinético |
| SG10201707600XA (en) | 2013-03-15 | 2017-11-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| CA2913078A1 (fr) | 2013-06-28 | 2014-12-31 | Biogen Ma Inc. | Lieur pouvant etre fendu par thrombine ayant un xten et ses utilisations |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| WO2015048330A2 (fr) | 2013-09-25 | 2015-04-02 | Biogen Idec Ma Inc. | Procédés d'inactivation de virus sur colonne |
| WO2015070014A1 (fr) | 2013-11-08 | 2015-05-14 | Biogen Idec Ma Inc. | Composé de fusion procoagulant |
| AU2015204646B2 (en) | 2014-01-10 | 2020-08-27 | Bioverativ Therapeutics Inc. | Factor VIII chimeric proteins and uses thereof |
| EP3160478A4 (fr) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Gène du facteur ix optimisé |
| CA3203273A1 (fr) | 2014-10-14 | 2016-04-21 | Halozyme, Inc. | Compositions d'adenosine deaminase-2, variants et methodes d'utilisation |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
| EP3337816B1 (fr) | 2015-08-20 | 2024-02-14 | Albumedix Ltd | Variants de l'albumine et leurs conjugués |
| CA3000742A1 (fr) | 2015-10-02 | 2017-04-06 | Silver Creek Pharmaceuticals, Inc. | Proteines therapeutiques bispecifiques pour la reparation de tissus |
| CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
| SI3411478T1 (sl) | 2016-02-01 | 2022-10-28 | Bioverativ Therapeutics Inc. | Optimirani geni dejavnika VIII |
| WO2017189978A1 (fr) | 2016-04-28 | 2017-11-02 | Emory University | Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées |
| EP3535585A1 (fr) | 2016-11-04 | 2019-09-11 | Aarhus Universitet | Identification et traitement de tumeurs caractérisées par une surexpression du récepteur fc néonatal |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| BR112019011198A2 (pt) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
| WO2018112362A1 (fr) | 2016-12-16 | 2018-06-21 | Biogen Ma Inc. | Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé |
| TW201831521A (zh) | 2017-01-31 | 2018-09-01 | 美商生物化學醫療公司 | 因子ｉｘ融合蛋白以及其製備方法及使用方法 |
| WO2018193033A1 (fr) * | 2017-04-20 | 2018-10-25 | Novo Nordisk A/S | Procédés de purification de protéines de fusion d'albumine |
| US20210163986A1 (en) | 2017-08-09 | 2021-06-03 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
| SG11202007114VA (en) | 2018-02-01 | 2020-08-28 | Bioverativ Therapeutics Inc | Use of lentiviral vectors expressing factor viii |
| CA3108799A1 (fr) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Molecules d'acide nucleique et leurs utilisations pour une therapie genique non virale |
| JP2022514465A (ja) | 2018-12-06 | 2022-02-14 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ｉｘ因子を発現するレンチウイルスベクターの使用 |
| WO2021067389A1 (fr) | 2019-09-30 | 2021-04-08 | Bioverativ Therapeutics Inc. | Formulations de vecteur lentiviral |
| JPWO2022030580A1 (fr) * | 2020-08-06 | 2022-02-10 | ||
| JP2024056667A (ja) * | 2022-10-11 | 2024-04-23 | Ｊｃｒファーマ株式会社 | 血清アルブミンと生理活性を有する蛋白質との融合蛋白質 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1463751T3 (da) * | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albuminfusionsproteiner. |
| EP1594530A4 (fr) * | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | Proteines hybrides d'albumine |
| EP1729795B1 (fr) * | 2004-02-09 | 2016-02-03 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
-
2006
- 2006-07-31 BR BRPI0614761-5A patent/BRPI0614761A2/pt not_active IP Right Cessation
- 2006-07-31 MX MX2008001865A patent/MX2008001865A/es not_active Application Discontinuation
- 2006-07-31 EP EP06813242A patent/EP1924596A4/fr not_active Withdrawn
- 2006-07-31 WO PCT/US2006/029391 patent/WO2007021494A2/fr active Application Filing
- 2006-07-31 JP JP2008526056A patent/JP2009504157A/ja not_active Withdrawn
- 2006-07-31 CA CA002618476A patent/CA2618476A1/fr not_active Abandoned
- 2006-07-31 AU AU2006280312A patent/AU2006280312A1/en not_active Abandoned
- 2006-07-31 KR KR1020087006077A patent/KR20080071119A/ko not_active Application Discontinuation
-
2008
- 2008-02-04 IL IL189246A patent/IL189246A0/en unknown
- 2008-02-11 TN TNP2008000064A patent/TNSN08064A1/en unknown
- 2008-03-07 MA MA30727A patent/MA29836B1/fr unknown
- 2008-03-10 NO NO20081233A patent/NO20081233L/no not_active Application Discontinuation
- 2008-03-12 EC EC2008008262A patent/ECSP088262A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1924596A4 (fr) | 2009-07-29 |
| MA29836B1 (fr) | 2008-10-03 |
| KR20080071119A (ko) | 2008-08-01 |
| BRPI0614761A2 (pt) | 2009-05-19 |
| CA2618476A1 (fr) | 2007-02-22 |
| EP1924596A2 (fr) | 2008-05-28 |
| WO2007021494A3 (fr) | 2007-07-26 |
| WO2007021494A2 (fr) | 2007-02-22 |
| ECSP088262A (es) | 2008-05-30 |
| NO20081233L (no) | 2008-05-09 |
| AU2006280312A1 (en) | 2007-02-22 |
| JP2009504157A (ja) | 2009-02-05 |
| MX2008001865A (es) | 2008-04-15 |
| TNSN08064A1 (en) | 2009-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL189246A0 (en) | Albumin fusion proteins | |
| IL176894A0 (en) | Albumin fusion proteins | |
| IL222924A0 (en) | Albumin fusion proteins | |
| IL197580A0 (en) | Albumin fusion proteins | |
| PL1830872T3 (pl) | Białka fuzyjne | |
| GB0426397D0 (en) | Fusion proteins | |
| IL204839A0 (en) | Albumin fusion proteins | |
| EP1934372A4 (fr) | Proteines hybrides ssb-polymerase | |
| EP1858546A4 (fr) | Proteines hybrides modifiees de transferrine | |
| ZA200801224B (en) | Albumin fusion proteins | |
| EP1594530A4 (fr) | Proteines hybrides d'albumine | |
| IL196889A0 (en) | Albumin-insulin fusion proteins | |
| ZA200709871B (en) | Interferon-IgG fusion | |
| GB0519965D0 (en) | Joint fusion peg | |
| EP1951862A4 (fr) | Vaccin à base de protéine de fusion portant un ligand cd40 | |
| IL196674A0 (en) | Exendin fusion proteins | |
| HK1118296A1 (en) | Stabilizer molecule-depleted albumin solution | |
| GB0423974D0 (en) | Proteins | |
| GB0426399D0 (en) | Fusion proteins | |
| GB0511861D0 (en) | Proteins | |
| AU2005905300A0 (en) | Fusion Protein | |
| GB0513505D0 (en) | Proteins | |
| GB0514481D0 (en) | Proteins | |
| GB0514788D0 (en) | Proteins | |
| GB0411678D0 (en) | Proteins |